Targeted Prodrug Design for the Treatment of Malignant Melanoma
Journal Title: Journal of Dermatology Research and Therapy - Year 2016, Vol 2, Issue 2
Abstract
Malignant melanoma is a serious health problem once the current chemotherapy exhibits resistance to traditional drugs. Several challenges must be overcome during drug design in order to increase the efficacy and safety of the new drugs. Therefore, the specific chemical release of cytotoxic agents near to the target is an attractive approach to improve the anticancer activity and reduce the systemic toxicity. Herein, this review article describes the advances in the development of targeted prodrugs for the treatment of malignant melanoma.
Authors and Affiliations
Keywords
Related Articles
- EP ID EP344155
- DOI 10.23937/2469-5750/1510019
- Views 136
- Downloads 0
Rosacea: A Potential Risk for Parkinson's Disease Development
Rosacea and Parkinson's disease (PD) are two completely different pathologies, with different outcomes, that share a common interesting feature as their proposed originating factor. Both conditions show inflammation as a...
Paraneoplastic Pemphigus
Paraneoplastic Pemphigus (PNP) is an autoimmune-related acquired bullous disease associated with neoplasia. Both humoral and cellular immunity are involved in the pathogenesis of PNP. Characteristically, PNP has a divers...
A Relapsing Polychondritis and Malignancies: A Case Report and Review of Literature
Some case reports and series presumed a link between malignancy and relapsing polychondritis. The most frequent described neoplasms have been hematological disorders especially myelodysplastic syndromes. Less commonly ha...
A Fatal Infection due to Gordonia Terrae
A 53-year-old man with a history of poliomyelitis underwent left total hip arthroplasty in December 2011. His past medical history was not significant except the medical conditions described disease. The patient had deve...
A Single-Site, Investigator Initiated Open-Label Trial of H.P. Acthar® Gel (Repository Corticotropin Injection) an Adrenocorticotropic Hormone (ACTH) Analogue in Subjects with Moderately to Severely Active Psoriatic Arthritis (PsA)
Although several therapeutic agents are available for psoriatic arthritis (PsA), each has limitations. Acthar® Gel (repository corticotropin injection) is FDA-approved for treatment of acute episodes or exacerbation of P...